Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Breast Cancer Poziotinib for HER2(+) Metastatic Breast Cancer Spectrum Pharmaceuticals, Inc.
Follicular Lymphoma Idelalisib for Treatment of Follicular Lymphoma Gilead Sciences
Solid Tumors STARTRK-2 Ignyta, Inc.
Prostate Cancer Prostate Cancer: TRUMPET Astellas Scientific & Medical Affairs, Inc.
Observational Miraca Registry of Hematopoietic Diseases Miraca Life Science
Observational CARIS Molecular Intelligence Registry Caris Life Sciences, Inc.
Non-Small Cell Lung Cancer Inivata Liquid Biopsy Inivata, Ltd.
Non-Small Cell Lung Cancer TR(ACE) Assay Clinical Specimen Study Biological Dynamics
Colorectal Cancer 2nd Line Colorectal Cancer Boston Biomedical, Inc
Pancreatic Cancer Artist 1 Pancreatic Cancer ARMO Biosciences
Multiple Myeloma Multiple Myeloma Melflufen Oncopeptides AB
Breast Cancer HER2(+) Breast Cancer Previously Treated with T-DM1 Daiichi Sankyo, Inc.
Breast Cancer Tesetaxel for HER2(-) Metastatic Breast Cancer Odonate Therapeutics, LLC
Ovarian, Fallopian, or Peritoneal Cancer Niraparib plus Bevacizumab as First Line Maintenance TESARO, Inc.
Pancreatic Cancer First Line Treatment with Napabucasin plus Nab-Paclitaxel and Gemcitabine Boston Biomedical, Inc.
Non-Small Cell Lung Cancer Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Small Cell Lung Cancer Second Line Irinotecan Versus Topotecan IPSEN Bioscience, Inc.
Acute Myeloid Leukemia Second Line Therapy for IDH1 Mutated Acute Myeloid Leukemia FORMA Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma Avelumab for Patients Previously Treated with Rituximab-Based Chemotherapy Pfizer
Urothelial Cancer Second Line Durvalumab plus Tremelimumab AstraZeneca
Hereditary Hemochromatosis Human Hepcidin for Patients Prescribed Therapeutic Phlebotomy La Jolla Pharmaceutical Company
Essential Thrombocythemia Ruxolitinib Versus Anagrelide in Patients Resistant or Intolerant to Hydroxyurea Incyte Corporation
Breast Cancer Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax George E. Peoples, Cancer Insight, LLC
Breast Cancer Ribociclib and Letrozole in HR Positive, HER2 Negative Disease Novartis Pharmaceuticals
Sample Collection SeraTrials Seratrials
Sample Collection MT Group MT Group, Inc
Observational Study informCLL Registry Study for Chronic Lymphocytic Leukemia Pharmacyclics LLC.
Observational Study Registry for Patients With Hodgkin's Lymphoma Bristol-Myers Squibb
Observational Study Multiple Myeloma Patient Registry Janssen Scientific Affairs, LLC
Observational Study MOST Myelofibrosis and Essential Thrombocythemia Registry Incyte Corporation
Observational Study Palbociclib in Real World Practice Breast Cancer Registry Pfizer
Renal Cell Carcinoma CANTATA: CB-839 and Cabozanitib versus Cabozanitib and Placebo Calithera Biosciences, Inc
Breast Cancer Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Disease Cancer Insight, LLC
Prostate Cancer SM88 in Patients with Prostate Cancer Tyme, Inc
Pancreatic Cancer SM88 in Patients with Previously Treated Metastatic Disease Tyme, Inc
Indolent Non-Hodgkin's Lymphoma Copanlisib with standard immunochemotherapy in relapsed iNHL Bayer HealthCare Pharmaceuticals, Inc.
Breast Cancer DS8201a in HER2+ Patients Previously Treated with Trastuzumab and a Taxane Daiichi Sankyo, Inc.
Autoimmune Hemolytic Anemia or Cold Agglutinin Disease PLAUDIT: A Study of APL-2 in Autoimmune Hemolytic Anemia Apellis Pharmaceuticals, Inc.
Breast Cancer ASCENT: Sacituzumab Govitecan in Triple Negative Breast Cancer Immunomedics, Inc.
Prostate Cancer ProSTAR: CPI-1205 in Metastatic Castration Resistant Prostate Cancer Constellation Pharmaceuticals, Inc.
Breast Cancer SPI-POZ-101: Poziotinib in HER2 Positive Breast Cancer Spectrum Pharmaceuticals, Inc
Triple Negative Breast Cancer VIOLETTE: A Study of Olaparib in Triple Negative Breast Cancer AstraZeneca
Breast Cancer DS8201a in HER2+ Patients Previously Treated with T-DM1 Daiichi Sankyo, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
Renal Cell Carcinoma ENTRATA: CB-839 in Renal Cell Carcinoma Calithera Biosciences, Inc.
RET Mutated Solid Tumors LIBRETTO: Loxo-292 in RET Mutated Solid Tumors Loxo Oncology, Inc.
Paroxysmal Nocturnal Hemoblobinuria PEGASUS: APL-2 for PNH Patients Being Treated with Exculizumab Apellis Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer Anamorelin for Weigh Loss or Anorexia Associated with Cancer Treatment Helsinn Healthcare SA